Glenmark Pharmaceuticals receives final approval for Desonide Cream, 0.05%

From USFDA

Glenmark Pharmaceuticals has received final approval from the United States Food & Drug Administration (USFDA) for Desonide Cream, 0.05%, the generic version of Desonide Cream, 0.05% of Perrigo New York Inc.

According to IMS Health sales data for the 12 month period ending May 2017, the Desonide Cream, 0.05% market1 achieved annual sales of approximately $44.6 million.

Powered by Capital Market - Live News